#London #United Kingdom #biotechnology #Virax Biolabs #Preferred Investment

Virax Biolabs Group Secures $3.3 Million

Virax Biolabs Group Limited has made headlines with its recent announcement of a substantial funding initiative, securing gross proceeds of approximately $3.3 million. This move comes as the biotech firm exercises its preferred investment options for the immediate purchase of ordinary shares. The agreement allows the purchase of up to 548,000 shares previously issued under a strategic financing plan.

Immediate Exercise of Investment Options

On July 9, 2026, Virax Biolabs declared its entry into a definitive agreement aimed at exercising certain outstanding preferred investment options originally issued in October 2023 and amended in December 2025. The initial exercise price of $10.00 per share has been reduced to $6.00 per share, creating a favorable financial opportunity for investors and the company alike. This decision is expected to significantly bolster the company’s finances and operational capabilities.

Impact on Shareholder Dynamics

As a part of this deal, the company will issue new unregistered Series A and Series B Preferred Investment Options, enabling shareholders to further capitalize on this reduced price opportunity. The Series A options will be exercisable following shareholder approval of an increase in the company's authorized shares and have a five-year expiration period. Meanwhile, the Series B options, also linked to the authorized share increase, will have an eighteen-month exercise window. These measures are designed to reinforce investor confidence and stimulate trading activities once the options become available.

Closing Anticipations

The company anticipates closing this offering around July 10, 2026, contingent on the satisfaction of customary closing conditions, further illustrating Virax's commitment to addressing financial health and stakeholder interests. The proceeds from this offering will be allocated primarily for working capital and general corporate purposes, aligning with the company’s strategic vision.

Future Perspectives

Despite the positive move, the pathway for these financial maneuvers is not without challenges. The firm acknowledges the need for registration under the Securities Act for the resale of shares issued from the newly exercised warrants, ensuring compliance with necessary regulations. Virax Biolabs aims to file registration statements with the SEC covering the resale of these newly issued shares, reflecting its commitment to transparency and regulatory adherence.

About Virax Biolabs Group Limited

Virax Biolabs is a biotechnology enterprise concentrating on innovative strategies to detect immune responses and T cell profiling. With a robust focus on developing diagnostic technologies for viral and immune-mediated diseases, the firm is well-positioned to address pressing health concerns, including Long COVID and other chronic immune dysfunctions. The principal programs under development, ViraxImmune™ and ImmuneSelect, are anticipated to significantly enhance diagnostic capabilities within healthcare.

This move represents a critical juncture for Virax Biolabs, demonstrating resilience and strategic growth in a competitive biotechnology landscape. The execution of the preferred investment options not only provides immediate financial benefits but also strengthens the company's position as it navigates future challenges in the biotech industry.